



SolAeroMed Inc  
Research Transition Facility  
3535 Research Rd NW  
Calgary T2L 2K8

email: [info@solaeromed.com](mailto:info@solaeromed.com)  
[www.solaeromed.com](http://www.solaeromed.com)

Newsletter #4 March 5, 2013

Dear SolAeroMed shareholders,

On behalf of the SolAeroMed team, I hope this update finds you healthy & interested in learning how your investment in our company is developing. We endeavor to keep you informed of developments through our revised web site at [www.solaeromed.com](http://www.solaeromed.com) and through these periodic newsletters.

We report that plans to develop S-1226 remain on track. Last month we learned that all our **method of treatment** claims were granted by the US patent office. Our patent claims are very broad, protecting method of treatment for asthma as well as other obstructive lung diseases and combination inhalation therapies making S-1226 a true platform technology. Furthermore, the US patent office awarded us 2 years of additional patent protection, recognizing that their prolonged discussions with us deserved compensation. S-1226 now boasts strong patent protection throughout the western world.

Another important development occurred late February when, we formally submitted our Phase I Clinical Trial Application for S-1226 to Health Canada. We anticipate a decision on whether our application is complete, or needs additional pre-clinical work sometime this month.. We may be ordered by Health Canada to do further preclinical work before being allowed to progress to human trials. However, we hope to receive a 'No Objection Letter' that will allow us to progress directly to first in human Phase I Clinical Trials –having healthy volunteers inhale the drug while clinicians monitor health, in order to demonstrate safety. Once a Phase I is successfully completed, we can progress development to Phase II trials to demonstrate efficacy (i.e. that S-1226 works in treating asthma).

Both the granting of the US patent and the submission of the Clinical Trial Application are important milestones in our development.

However, SolAeroMed faces a significant challenge. Though SolAeroMed maintains a lean burn rate and still possesses sufficient funds allowing us to function through 2013/4, along with Research & Development grant support, SolAeroMed will need significant new funding before initiating any human clinical trials - our best estimates suggest this will total nearly \$3 million over the next 2 years. While we continue to seek non-dilutive grant support, our company will require further dilutive capital investment for prior to starting our Phase I clinical trial. We are actively seeking Angel and Venture Capital investment in Canada, USA and Europe through our external network of science and business colleagues.

We endeavor to keep SolAeroMed shareholders informed of developments through [www.solaeromed.com](http://www.solaeromed.com) and via periodic newsletters.

Sincerely

Dr John Dennis, PhD  
CEO